IQ Consortium® Leadership

IQ's Board of Directors includes representatives from all IQ member companies and is led by a Chair and Vice-Chair.

Timothy Watson, Ph.D., Gilead Sciences
IQ Consortium Chair

Dr. Timothy Watson, Ph.D. is Vice President-Head of CMC Regulatory Affairs, Gilead Sciences. Prior to joining Gilead, Tim led Pfizer’s CMC Advisory Office, which is a collection of global Pfizer technical and regulatory experts that provides guidance and direction to project teams to mitigate regulatory risk and integrate CMC policy with product strategies, while developing and advocating policy positions (internally and externally) in conjunction with QO. The Advisory Office includes in-region team members to support AFME, LAT and AM, A-Pacific portfolio execution, and CMC policy, including Pfizer’s China’s CMC product portfolio team. In addition to Advisory Office responsibilities, Tim was instrumental in the development and implementation of Quality by Design, ICHQ12, etc., and advocated for global regulatory harmonization and mutual reliance, serving as a PhRMA representative to several ICH Expert and Implementation Working Groups (EWG and IWG) since 2009. Tim served as a PhRMA EWG member on the ICHQ11 regulatory guidance document for drug substance, the Rapporteur for the ICHQ11 Q and A Starting Material IWG, PhRMA IWG member for the ICHQ7 Q and A team, and continues to serve as the PhRMA ICHQ3C EWG lead. Tim was nominated as the PhRMA IWG/ EWG lead for ICHQ9 revision (starting in 2020). Tim serves on the Board of Directors for the International Consortium for Innovation and Quality (IQ), co-Chairs the ISPE Global Regulatory and Quality Harmonization Council and is a member of the Regulatory Steering Committee, and was Pfizer’s lead representative on the PhRMA Global Quality and Manufacturing Work Group (GQM WG). Tim authored numerous publications and presentations and received multiple awards for regulatory contributions (e.g., AAPS Regulatory Section Recognition Award in 2014).

Tim began his career at Marion Merrell Dow (1994) in chemical research and development (CRD) as an API small molecule process chemist, where his responsibilities involved developing new API processes, manufacturing the first GMP API bulk clinical supplies, and technology transfers to commercial facilities/ CROs, etc. In 2000, Tim joined Pfizer, where he continued with process chemistry development responsibilities with a focus on post-proof of concept projects and commercialization up until 2009, when he joined CMC. Tim holds a Ph.D. from The Ohio State University, under the direction of Dr. Leo Paquette


Philip Floyd, Ph.D., GSK
IQ Consortium Vice-Chair

Phil Floyd received his PhD in Analytical Chemistry under Jonathan Sweedler at University of Illinois.  While at Illinois he performed the research for his dissertation at the Beckman Institute of Technology working collaboratively with varying disciplines, such as Molecular and Cellular Biology, Computational Chemistry, Engineering and Physical Chemistry, in performing research on neuronal signaling pathways.

Prior to joining GSK, Phil spent 2 years at Johnson & Johnson in Analytical Development as bench scientist responsible for the development, validation and technical transfer of analytical methods in support of their RX and OTC portfolio.  He joined GSK in PA in 2001 and served as Analytical Lead for Altabax, Promacta/Revolade, and Horizant/Solzira from Candidate Selection through successful NDA/MAA File and Launch.  In 2007 he moved to GSK site in RTP, NC to serve as Team Leader within Product Development, leading a diverse group of formulators and analytical scientists in the development of multiple Phase III assets.  In addition, he represented GSK R&D in the execution of Due Diligences which directly led to acquisition of assets by GSK.  Phil also served for a number of years on the Japan CMC Steering Team representing the Late Stage Portfolio intended for entry into the Japan Market. 

In 2013, he returned to PA to become US Senior Director of Analytical Development for both large and small molecules and continues to serve in this capacity with a department of over 170 scientists within Analytical Sciences and Development with a current portfolio of 30 assets, including multiple successful NDA/MAA/JNDA over past several years including Cabotegravir, Daprodustat, and Blenrep in 2021.  Phil has over 30 scientific presentations, including invited panel speaker in collaboration with Pfizer and FDA at the most recent DIA Conference, and has over 20 publications in peer reviewed journals.